Research
Hormonal
Semaglutide (subcutaneous and oral) demonstrates cardiovascular safety (non-inferiority) and potential renal benefits in high-risk Type 2 Diabetes patients, though it may increase retinopathy complications.
For those with Type 2 Diabetes and heart disease risk, semaglutide is safe for the heart and may protect kidney function. However, patients with existing diabetic eye disease should be monitored closely as rapid blood sugar improvement can sometimes worsen retinopathy.
StrongQualifiesHIGH confidence
The primary outcome composite (first occurrence of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) occurred in 6.6% in the semaglutide group vs. 8.9% in the placebo group (P<0.0001 for noninferiority).
Why this rating
Based on SUSTAIN-6 and PIONEER-6 cardiovascular outcome trials.
Source
Future perspectives in diabesity treatment: Semaglutide, a glucagon‑like peptide 1 receptor agonist (Review)
Mariana Cornelia Tilinca et al. · Experimental and Therapeutic Medicine · 2021
DOI 10.3892/etm.2021.10601
narrative_reviewCited 26×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide (2.4 mg once-weekly subcutaneous) significantly reduces body weight in adults with obesity or overweight with comorbidities compared to placebo.Strong
- Semaglutide (0.5-1.0 mg once-weekly subcutaneous) lowers HbA1c and reduces body weight more effectively than other common GLP-1 RAs (exenatide, dulaglutide, liraglutide) and SGLT-2 inhibitors (canagliflozin) in Type 2 Diabetes.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →